BHC(SH:600721)2022-03-29 16:00Financial Performance - In 2021, the company achieved operating revenue of CNY 281.35 million, a year-on-year increase of 232.84% compared to CNY 84.53 million in 2020[20]. - The net profit attributable to shareholders of the listed company for 2021 was CNY 59.83 million, a significant turnaround from a net loss of CNY 319.77 million in 2020, representing an increase of 118.71%[20]. - The company reported a net cash flow from operating activities of CNY 34.72 million in 2021, compared to a negative cash flow of CNY 23.28 million in 2020, marking a 249.14% improvement[20]. - The total assets of the company at the end of 2021 were CNY 982.31 million, a slight increase of 0.78% from CNY 974.68 million at the end of 2020[20]. - The net assets attributable to shareholders of the listed company increased by 10.02% to CNY 681.30 million at the end of 2021, up from CNY 619.26 million at the end of 2020[20]. - The basic earnings per share for 2021 were CNY 0.1595, a recovery from a loss of CNY 0.8202 per share in 2020, reflecting an increase of 119.45%[21]. - The company’s weighted average return on equity improved to 9.22% in 2021, up by 50.80 percentage points from -41.58% in 2020[21]. - The company reported a net profit attributable to shareholders for the reporting period was CNY 59.8271 million, achieving a turnaround from loss to profit, primarily due to a debt restructuring gain of CNY 47.5566 million from an agreement with Western Oasis[22]. - The total revenue for the year was CNY 281.3530 million, a year-on-year increase of 232.84% from CNY 84.5304 million[30]. - The company’s other income increased significantly by 926.89% to CNY 49.56 million, primarily due to the transfer of a 30% stake in a subsidiary[56]. Research and Development - The company reported significant growth in pharmaceutical research and clinical study contracts, with an increase in projects obtaining production licenses and passing consistency evaluations compared to the previous year[21]. - The company completed 300+ generic drug R&D applications for over 200 pharmaceutical companies, including more than 50 of the top 100 pharmaceutical companies in China[29]. - The company applied for 15 new invention patents during the reporting period, with 4 patents authorized in China and 1 in the United States[32]. - Pharmaceutical R&D revenue reached CNY 140.14 million, an increase of 546.62% year-on-year, with costs decreasing by 51.01%, resulting in a gross margin of 44.43%[60]. - Clinical trial revenue was CNY 106.70 million, up 215.46% year-on-year, with costs increasing by 46.67%, leading to a gross margin of 15.05%[61]. - The company has developed over 350 new drug technologies and obtained more than 100 Chinese and international PCT technology invention patents[48]. - The company is focused on developing gene markers for liver cancer detection, enhancing its product portfolio in oncology[114]. Market Strategy and Expansion - The company aims to enhance its core competitiveness in pharmaceutical R&D and clinical research, focusing on strategic acquisitions to expand its industry chain[91]. - The company plans to upgrade its R&D services to high-end generic drug development, leveraging existing technical advantages[91]. - The company is expanding its clinical services from generic drugs to innovative drug development, focusing on high-value-added services[92]. - The company plans to strengthen its technical capabilities and service capacity through the establishment of a comprehensive "investment, financing, and research" cooperation channel[94]. - The company is exploring potential mergers and acquisitions to further enhance its product portfolio and market reach, with a focus on strategic partnerships[157]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in international sales by 2023[156]. Corporate Governance and Compliance - The company has held 12 board meetings and 6 shareholder meetings in 2021, ensuring effective governance and decision-making[102]. - The company has not identified any significant differences in governance compared to regulatory requirements, ensuring compliance with laws and regulations[109]. - The company has taken measures to maintain independence from its controlling shareholders, ensuring no significant impact from related business activities[109]. - The company has committed to transparency in disclosing related party transactions to protect the interests of all shareholders[155]. - The company will ensure that any necessary related party transactions are conducted in accordance with legal and regulatory requirements[154]. - The company has established a robust investor relations management framework to facilitate effective communication with stakeholders[108]. Human Resources and Management - The company has a professional technical team of 722 people, with over 90% holding a bachelor's degree or above, and 143 holding master's or doctoral degrees[29]. - The number of R&D personnel was 586, making up 81.16% of the total workforce[73]. - The company has a diverse management team with extensive experience in finance, pharmaceuticals, and clinical research, enhancing its strategic capabilities[113]. - The total pre-tax remuneration for directors and senior management during the reporting period amounted to 6.99 million yuan[112]. - The company has a structured governance framework, with clear roles and responsibilities for its board members and management team[118]. Financial Management and Investments - The company has engaged in structured deposits totaling ¥26,500,000 and non-principal guaranteed bank wealth management products amounting to ¥27,900,000[177]. - The company has a commitment to continue its wealth management plans in the future, reflecting a proactive approach to asset management[178]. - The company has a series of structured deposits with annualized returns ranging from 1.48% to 3.08%, with total expected returns of ¥42,786.52 from various investments[178]. - The company has successfully recovered all amounts from its wealth management products, indicating effective cash management strategies[178]. - The company has a total of ¥6,297,615.37 in guarantees outstanding to subsidiaries as of the reporting period[175]. Future Outlook - The company aims for a revenue and net profit growth of no less than 20% in 2022 compared to the previous year[94]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[160]. - The company has set a revenue target of 1.5 billion yuan for 2022, indicating an ambitious growth strategy with an expected increase of 25%[156].